OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Shannon N. Westin, MD, MPH

home / authors / shannon-n-westin-md-mph

Articles

Advertisement

Dr. Westin on Remaining Challenges in Endometrial Cancer

Dr. Westin on Remaining Challenges in Endometrial Cancer

September 10th 2020

Shannon N. Westin, MD, MPH, discusses remaining challenges in endometrial cancer.

Read More


Dr. Westin on Novel Targets in Endometrial Cancer

Dr. Westin on Novel Targets in Endometrial Cancer

May 12th 2020

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Read More


Dr. Westin on Novel Targets in Endometrial Cancer

Dr. Westin on Novel Targets in Endometrial Cancer

May 11th 2020

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Read More


Dr. Westin on Advances Made With PARP Inhibitors in Ovarian Cancer

Dr. Westin on Advances Made With PARP Inhibitors in Ovarian Cancer

January 18th 2019

Shannon N. Westin, MD, MPH, associate professor, The University of Texas MD Anderson Cancer Center, discusses advances made with PARP inhibitors in the ovarian cancer treatment paradigm.

Read More


Dr. Westin on Emerging PARP Inhibitors in Ovarian Cancer

Dr. Westin on Emerging PARP Inhibitors in Ovarian Cancer

November 20th 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses PARP inhibitors being tested in clinical trials.

Read More


Dr. Westin on PARP Resistance in Ovarian Cancer

Dr. Westin on PARP Resistance in Ovarian Cancer

October 9th 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

Read More

Latest Conference Coverage

Dr Deek on the Investigation of Immune Cell Infiltration in MIBC

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

Dr Hoppe on the Rationale for the CheckMate 744 Trial in Hodgkin Lymphoma

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact